Topics

Human medicines European public assessment report (EPAR): Symtuza, darunavir / cobicistat / emtricitabine / tenofovir alafenamide, HIV Infections, Date of authorisation: 21/09/2017, Revision: 7, Status: Authorised

10:00 EDT 11 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Symtuza, darunavir / cobicistat / emtricitabine / tenofovir alafenamide, HIV Infections, Date of authorisation: 21/09/2017, Revision: 7, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Symtuza, darunavir / cobicistat / emtricitabine / tenofovir alafenamide, HIV Infections, Date of authorisation: 21/09/2017, Revision: 7, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Symtuza, darunavir / cobicistat / emtricitabine / tenofovir alafenamide, HIV Infections, Date of authorisation: 21/09/2017, Revision: 7, Status: Authorised"

Quick Search

Relevant Topics

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...